Fig. 1: MVA-specific humoral and cellular responses in COH04S1-vaccinated healthy adults.

a COH04S1 schedule and dosing in healthy adults. Large circles indicate time of vaccination. MVA-specific humoral responses. MVA-specific IgG endpoint titers (b), and neutralizing antibodies (NAb) (c) were measured by ELISA and neutralization assay in subjects before vaccination, post-prime vaccination, and at one- and five-months post-booster vaccination with COH04S1 at dose-level (DL) 1 (DL1/DL1 [lavender circles] and DL1/placebo/DL1 [upward purple triangles]), DL2 (DL2/DL2 [downward pink triangles]), and DL3 (DL3/DL3 [green squares]) (n = 5 subjects/group). Placebo controls (n = 4 subjects [gray diamonds]) were included. c MVA-specific cellular responses. MVA-specific CD8⁺ and CD4 + T cells co-expressing CD107 (blue circles and downward pink triangles, respectively) or CD69 (upward purple triangles and green squares, respectively) markers were measured by intracellular IFNγ staining in subjects described in b-c. Box plots show 25th–75th percentiles, lines indicate medians, whiskers go from minimum to maximum values. Two-way ANOVA followed by Tukey’s multiple comparison test was used in (b, c) after log transformation. Two-tailed Wilcoxon paired T test was used in (d). P values < 0.05 are shown. Dotted lines in b-c represent the lower limit of detection of the assay.